Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

MEZAVANT XL GASTRO-RESISTANT PROLONGED RELEASE TABLET 1200MG [SIN14999P]

Active ingredients: MESALAZINE

View product's general information
Last updated on 9 October 2026

Product Info

MEZAVANT XL GASTRO-RESISTANT PROLONGED RELEASE TABLET 1200MG

[SIN14999P]

Product information

Active Ingredient and Strength

MESALAZINE - 1,200 MG

Dosage Form

TABLET, DELAYED RELEASE

Manufacturer and Country

COSMO S.P.A. - ITALY

Registration Number

SIN14999P

Licence Holder

TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

A07EC02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications
For the induction of clinical and endoscopic remission in patients with mild to moderate, active ulcerative colitis. For maintenance of remission.

Dosing

4.2 Posology and method of administration
Mezavant XL is intended for once daily, oral administration. The tablets must not be crushed or chewed and should be taken with food.

Adults, including the elderly (>65 years)
For induction of remission: 2.4 to 4.8 g (two to four tablets) should be taken once daily. The highest dose of 4.8 g/day is recommended for patients not responding to lower doses of mesalazine. When using the highest dose (4.8 g/day), the effect of the treatment should be evaluated at 8 weeks.

For maintenance of remission: 2.4 g (two tablets) should be taken once daily.

Children and adolescents
Mezavant XL is not recommended for use in children below the age of 18 years due to a lack of data on safety and efficacy.

Specific studies have not been performed to investigate Mezavant XL in patients with hepatic or renal impairment (see sections 4.3 and 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Contraindications

4.3 Contraindications
History of hypersensitivity to salicylates (including mesalazine) or any of the excipients of Mezavant XL.
Severe renal impairment (GFR <30 ml/min/1.73m2) and/or severe hepatic impairment.